Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I

Journal of Endocrinological Investigation

Volumn 34, Issue 9 SUPPL., 2011, Pages

  Scacchi, M ^a,b   Carzaniga, C ^a   Vitale, G ^a,b   Fatti, L M ^b   Pecori Giraldi, F ^a,b   Andrioli, M ^a   Cattaneo, A ^a   Cavagnini, F ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Acromegaly; GH; IGF I; Oral glucose tolerance test; Somatostatin

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOPAMINE AGONISTS; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; ROC CURVE; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856270767     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7802     Document Type: Article

References (25)

1. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89: 667-74. (Pubitemid 38269875)
2. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a Consensus Statement. J Clin Endocrinol Metab 2000, 85: 526-9. (Pubitemid 32273628)
3. Melmed S, Casanueva F, Cavagnini F, et al. Consensus Statement: medical management of acromegaly. Eur J Endocrinol 2005, 153: 737-40. (Pubitemid 43020222)
4. Melmed S, Colao A, Barkan A, et al Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509-17.
5. Giustina A, Chanson P, Bronstein MD, et al Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95: 3141-8.
6. Machado EO, Taboada GF, Neto LV, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 2008, 18: 389-93. (Pubitemid 351958110)
7. Resmini E, Barreca A, Ferone D, Giusti M, Sidoti M, Minuto F. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. Clin Endocrinol (Oxf) 2005, 63: 294-7. (Pubitemid 41233446)
8. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002, 87: 3142-7. (Pubitemid 34816356)
9. Cozzi R, Attanasio R, Grottoli S, et al. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? J Endocrinol Invest 2004, 27: 1040-7.
10. Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 2008, 93: 1324-30. (Pubitemid 351519728)
11. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002, 87: 3537-42. (Pubitemid 34879493)
12. Trainer PJ. Editorial: acromegaly-consensus, what consensus? J Clin Endocrinol Metab 2002, 87: 3534-6.
13. Freda PU, Post KD, Powell JS, Wardlaw SL Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998, 83: 3808-16. (Pubitemid 28513555)
14. GuIIu S, Keles H, Delibasi T, Tonyukuk V, Kamel N, Erdogan G. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol 2004, 150: 465-71.
15. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 658-61. (Pubitemid 38269873)
16. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004, 89: 495-500. (Pubitemid 38269847)
17. Jayasena CN, Wujanto C, Donaldson M, Todd JF, Meeran K. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients. Clin Endocrinol (Oxf) 2008, 68: 36-41. (Pubitemid 350243479)
18. Taboada GF, Correa LL, de Oliveira Machado E, et al. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR. Growth Horm IGF Res 2007, 17: 77-81.
19. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009, 94: 523-7.
20. Sherlock M, Aragon Alonso A, Reuten RC, et al. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf) 2009, 71: 74-81.
21. Colao A, Pivonello R, Cavallo LM, et al. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 2006, 65: 250-6. (Pubitemid 44079691)
22. Minuto F, Resmini E, Boschetti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 2004, 61: 138-44. (Pubitemid 38951657)
23. Arafat AM, Möhlig M, Weickert MO, et al. Growth hormone re-sponse during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in health controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 2008, 93: 1254-62. (Pubitemid 351519718)
24. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009, 94: 1500-8.
25. Bianchi A, Giustina A, Cimino V, et al. Influence of growth hormone receptor d3 and full-lenght isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 2009, 94: 2015-22.